DMD and Duchenne muscular dystrophy: We have now shown the safety and preliminary efficacy data from a first-in-human study of DEC01 therapy – a novel DMD treatment that is designed to restore dystrophin expression in the muscle tissues affected by DMD [36, 37, 40–42], without eliciting an immune response [45].